Crossmark

Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner

Crossref DOI link: https://doi.org/10.1007/s13402-023-00789-7

Published Online: 2023-03-20

Published Print: 2023-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Shan

Zhang, Nai-Qi

Xu, Chun-Jie

Huang, Wu-Qing

Li, Dong-Xue

Li, Jun

Yao, Lin-Li

Sundquist, Kristina

Sundquist, Jan

Jiang, Shu-Heng

Xing, Xin

Hu, Li-Peng

Zhang, Zhi-Gang

Ji, Jianguang

Zhang, Xue-Li
Funding

Funding for this research was provided by:

the National Natural Science Foundation of China (82073023, 81902370, 82103357, 92168111)

Innovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20210802)

the National Natural Science Foundation of Shanghai (21ZR1461300, 22ZR1460000)

Shanghai Sailing Program (21YF1445200)

the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20181708)

Program of Shanghai Academic/Technology Research Leader (19XD1403400)

Medicine and Engineering Interdisciplinary Research Fund of Shanghai Jiao Tong University (YG2021ZD08)

the Swedish Research Council (2021-01187)

MAS Cancer

Shanghai Municipal Health Commission (202040092)
License Information

Text and Data Mining valid from 2023-03-20

Version of Record valid from 2023-03-20
More Information

Article History

Accepted: 21 February 2023

First Online: 20 March 2023

Declarations

:

: The nationwide cohort study (Dnr 2012/795) was approved by The Ethics Committee in Lund, Sweden approved (February 6, 2013). Animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai JiaoTong University.

: The authors declare no potential conflicts of interest.

Document is current

Any future updates will be listed below